Table 3 Final combined AE multivariate models of associations between adverse events and objective response (OR; complete or partial response) for mRCC patients receiving sunitinib on Schedule 4/2 or any dose/schedule

From: Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

  

Schedule 4/2

Any dose/schedule

Adverse event at any time point

End point

Odds ratio

95% CI

P-valuea

Odds ratio

95% CI

P-valuea

Neutropenia

OR

0.53

0.35–0.79

0.0021

0.44

0.30–0.66

<0.0001

Hypertension

OR

0.20

0.12–0.34

<0.0001

0.20

0.12–0.32

<0.0001

Hand–foot syndrome

OR

0.43

0.27–0.68

0.0003

0.43

0.28–0.66

0.0001

Asthenia/fatigue

OR

0.44

0.28–0.70

0.0005

0.48

0.32–0.73

0.0007

Thrombocytopenia

OR

0.54

0.33–0.87

0.0118

0.55

0.35–0.86

0.0098

  1. Abbreviations: AE=adverse event; CI=confidence interval; mRCC=metastatic renal cell carcinoma.
  2. aTwo-sided Wald chi-squared test (all results were statistically significant).
Back to article page